Hi everyone, I'm Maggie McGrath, editor of Forbes Women, reporting here from NASDAQ market site.

Today, 7 million Americans have Alzheimer's disease, and the Alzheimer's Association expects that number to nearly double within the next 25 years.

Within this environment, women are more likely to experience

neurocognitive decline than men are, and there is no one cure or treatment that has come to

market. Our next guest is trying to change this reality. She is Stella Saraff, the founder and

CEO of Spinogenics, a drug discovery and development company

that is trying to not just prevent neurocognitive decline, but reverse it in some cases.

Stella, thank you so much for being here.

Thank you for having me, Maggie.

So I don't want to say that your drugs can restore memory because that feels like overstating it a little bit.

But can you talk about exactly what you are spearheading through your company?

Yeah, I founded Spinogenics in 2016 with the goal to create synaptic regenerative treatments to combat a lot of brain diseases

and Alzheimer's being one of the, I would say, one of our big indications that we're very excited for.

By working at the synaptic levels, your synapses are the fundamental building blocks that allow your neurons to communicate

and actually control the way you plan, think, movement, talking, even sight, and even breathing.

So we are very excited because we have a small molecule drug

in clinical development working at, restoring those synapses,

those connections that stop working.

And you can imagine by doing that,

when you restore those connections, you can actually regain function.

So our hope is that we can restore memory.

Our hope is that someone who, let's just say, you still enjoy reading a book, can now pick up a book and actually finish that person with Alzheimer's.

...